FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER
In a study published online in The New England Journal of Medicine, Alice T. Shaw and coauthors presented the results of CROWN, a phase III trial evaluating the third-generation tyrosine kinase inhibitor (TKI) lorlatinib in patients with advanced non–small cell lung cancer (NSCLC) harboring an ALK translocation. ALK translocation and mutations occur in 2% to 7% […]
FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER Read More »
